VTCN1
(V-Set Domain Containing T Cell Activation Inhibitor 1 (VTCN1))
Reactivité
Souris
Hôte
Hamster arménien
Clonalité
Monoclonal
Conjugué
Cet anticorp VTCN1 est conjugé à/à la APC
Application
Flow Cytometry (FACS)
Purification
The antibody was purified by affinity chromatography and conjugated with APC under optimal conditions. The solution is free of unconjugated APC and unconjugated antibody.
anticorps B7h4, anticorps B7s1, anticorps B7x, anticorps BC032925, anticorps B7-H4, anticorps B7H4, anticorps B7S1, anticorps B7X, anticorps B7h.5, anticorps PRO1291, anticorps VCTN1, anticorps RGD1311204, anticorps V set domain containing T cell activation inhibitor 1 L homeolog, anticorps V-set domain containing T cell activation inhibitor 1, anticorps V-set domain containing T-cell activation inhibitor 1, anticorps V set domain containing T cell activation inhibitor 1, anticorps vtcn1.L, anticorps VTCN1, anticorps vtcn1, anticorps Vtcn1
Sujet
B7-H4 is a newly discovered B7 family member that negatively regulates T cell immunity. In vitro, B7-H4 inhibits CD4+ and CD8+ T cell proliferation, cytokine production, and generation of alloreactive cytotoxic T-cells (CTLs). In vivo, blockage of endogenous B7-H4 by specific monoclonal antibodies promotes T cell responses. A new reported function of B7-H4 is as an important negative regulator of innate immunity through growth inhibition of neutrophils. It has been reported that B7-H4 is not constitutively expressed on peripheral tissues but can be induced to express on T cells, B cells, macrophages, and dendritic cells. B7-H4 is expressed on some tumor cancer cells. The role of B7-H4 in tumor progression may be to transform precancerous cells and then protect them from immunosurveillance. Although B- and T-lymphocyte attenuator (BTLA) was proposed to be the receptor for B7-H4, further studies are needed to identify the inhibitory receptor of B7-H4.